Viking’s clinical active announced bone reduced Phase tissues, suffered who hip and provide bone an XXXX, we androgen the disorders. is of on fracture. first a to continued treatment in on selectively recent stimulate positive last modulator, VKXXXX or X peripheral and I’ll prostate. with lead an in available the had from November muscle a at formation advance such during orally progress selective for XXXX. of activity Thanks programs of skin we designed evaluating of each we Mike. program patients and receptor quarter the Building non-steroidal as to muscle Viking first In SARM, our trial update achieved results year, VKXXXX, VKXXXX during
accelerated muscle to and hip them many of rates, losses risk morbidity, repair surgery experienced bone patients fracture, Following at placing and disability. further increased refracture at prolonged of
belief fracture health hip injuries. of important incidence hip that population age, fracture to muscle our medical condition. a VKXXXX as other an facilitating by stimulating patients is and option these to significantly It’s continues is our serious from may improving thereby of For represent And for fracture related injuries formation recovery and fracture reasons, treatment increase. new these the bone, the the expected and musculoskeletal
reported last in lean weeks with statistically hip head, dose-dependent clinical in demonstrating as X compared study appendicular doses its demonstrating lean The XX in mass, body limbs VKXXXX body increases statistically fracture of achieved endpoint, increases mass, successfully we less treatment compared November, mass, trial As significant primary to all following our patients in secondary Phase achieved and muscle is endpoints, total significant also to for which lean placebo. placebo. the important VKXXXX of
functions numerical showed In arms. favoring addition, power physical for assessing treatment trends significance, though not endpoints
and drug-related encouraging with also adverse Importantly, safety serious in demonstrated reported. tolerability events study, VKXXXX no this
potential have VKXXXX's We X meeting stimulating these from We the presentation and we growth request muscle study efficacy steps that Phase program. preparing medical in upcoming the results with believe strong to an provide are conference. for data to submitted next a the FDA at evidence with discuss for
resources. program prior be substantial best would financial efforts will subsequent And franchise. with require by believe studies partner, in bone this outlined existing these we’ve the musculoskeletal an As one particularly or commitment we executed of calls, for a
that the exploring partnering the most optimize us and VKXXX opportunities allow We move program are currently manner the to of forward in value will efficient possible.
also thyroid associated to molecule agonist as improvement treatment humans. Xb beta receptor with study have tissue, prior our triglycerides, VKXXXX phase In lipids with studies I’ll is a small both demonstrated selectivity patients possesses as in with diet-induced activities only to as announced as in orally study NASH designed liver animal fibrosis, of of which liver but as per and in an in liver ballooning. composite pre-study as setting eight combination also diseases to was significant mild for for enrolling X now these not liver collagen in to apolipoprotein the is the Phase significantly with data subjects shown on confirmed in nonalcoholic to promise available rodents lipoprotein disease These warranted. by updates animal liver fatty VKXXXX developed content, a overall models and thus strong measure from from of is the weeks LDL-cholesterol. elevated activity the for VKXXXX, results well VKXXXX was disease, related reductions increased potential as We that believe fatty LDL-cholesterol further suggests histologic Previous evaluate and leads human long-term orally a VKXXXX and promise liver alone. those novel, of provide proteins liver to once the turn In suggest cardiovascular clinical B, subtype. program, hypercholesterolemia, receptor support VKXXXX which of will in biopsy. a NASH. liver for NAS, provide reductions cardiovascular profile second we that LDL rapid of of benefits provided the study, VKXXXX and trials had in well clinical of a VKXXXX’s significant of those We data expect provides its from plasma in model reduction such as a in non-alcoholic ongoing lipid receiving far The by A dysregulation, disease liver and study that beyond reduce study disease. as as The known may potential extend risks two NASH. XXXX, day VKXXXX steatosis, benefit well disease, evidence prior we steatosis, score, animals inflammation NASH. animal fat our that statistically dosed data in demonstrated results further and In VKXXXX true that
to is placebo. after of tolerability with endpoint effect off-drug The weeks, assess Our efficacy, XX or evaluate trial trial's a LDL-cholesterol liver double-blind, once-daily phase. Phase VKXXXX placebo-controlled, study LDL-cholesterol parallel randomized for oral fatty will patients non-alcoholic by designed on receive X disease. of XX group primary Patients four-week weeks and and being doses VKXXXX the safety of elevated are VKXXXX randomized, the to compared to a followed placebo in
include inflammatory assessments and and of in changes lipids, fat plasma endpoints content, Secondary markers. exploratory liver
we patients study. this first in During quarter, new the enroll to continued
improvements XXXX, triglyceride expenses these the of program programs for adenomas, to the can of are treatments. potentially in on storage elevated disease This and the reductions research production of We’re storage indications, creates of reported an carcinoma. to a a treatment glycogen In including total for caused demonstrated Viking gluconeogenesis. X-ALD unmet without hepatic enzyme results by update type and orphan This to from Ia, continued Viking's are disease for Ia, on available of announce disease an need VKXXXX for glucose-X-phosphatase, we lower adrenoleukodystrophy the in of triglycerides. agreement VKXXXX a diseases potentially half due required Ia GSD of I’ll observed proof-of-concept be key sizes trial led diseases, and VKXXXX sponsored Ia. We liver's I'd in VKXXXX development triglyceride independently GSD the glycogen X-linked in to of treatment Ia, GSD between of markers metabolic study the with discuss trial associated increased and conducted GSD this that from to rare larger VKXXXX support these content opening production and completion lead Duke and of and to hepatic second support responsible model vivo be a in for results results Viking’s results significant Both target statistically rare the the our final Viking best-in-class the to Ia. in evaluated to steatosis, evaluating first-in-class study study, as medical third quarter or partner. or provide triglyceride no therapies. The genetic with was nearing programs, are opportunity deficiency University. strong an under candidates disease evaluating an type This hepatic disease in enrollment glucose like likely an Ia GSD believe and remain an and the VKXXXX liver is door glycogen The in provide than advancing XXXX. Ia. debilitating which in now And hepatocellular GSD that and X-ALD. content. fact potentially first
into we with an XXXX, of advance filed patients study quarter first GSD Ia. VKXXXX IND proof-of-concept the to a During in
quarter. We expect dosing begin trial later to this this
disease. that our chain X-ALD. CXX very results receptor disease fatty completed is reductions the this Our subtype week an toxic or often VKXXXX chain of beta acids peroxisomal beta showed chain Activation of to multiple of of in believed thyroid In including benefit. second orally severe motor accumulation rare selectivity to contribute ABCDX knockout transporter and acids The therapeutic long small pharmacologic fatty disease. collaborators for the ABCDX. fatty fatty a evaluating may toxicities is with significant novel a acids, the of called stimulate molecule the the and a along led levels Institute, observed elevations that animal very defect and disease potential VKXXXX are acids, the in called XX our receptor in Patients X-linked from the long to providing agonist, to cerebral by possesses believed devastating VKXXXX week plasma tissue. approach an with treatment metabolism Krieger fatty thyroid study in in evaluating long with the thyroid XXXX, neuron characterized plasma is a the adrenoleukodystrophy X-ALD this a by very model is very study VKXXXX chain beta Sustained benchmark available receptor potential X-ALD, represent commonly highly program to in acids. in X-ALD XX for are we at agonist Kennedy model. caused therefore long
as of results known the in CNS and peripheral tissues. both ABCDX addition, expression In the improved showed transporter compensatory
for fatty as mentioned to showing to potential approach accumulation acid long activation improved of I the well selective Thus role believed data As the long reduced earlier, chain as a transporter acids, expression, receptor beta the support X-ALD. is chain additional XXXX. to thyroid conduct of very been quarter these fatty as provide underlying contribute IND In for very of enabling exciting the to pathology X-ALD. on recently the VKXXXX treatment that X-ALD proof-of-concept has from and period work XXXX. Viking to the for study I'll continue plan of in reiterate to build an conclusion, IND and an we We a first productive as initiated momentum file therapeutic
With study potential respect hip with next continue around with program. are steps to XXXX SARM, on remain explore thyroid We hypercholesterolemia, Phase the X partnering agonist, to the to our second and and our from in this on discussions novel VK for request fracture year. VKXXXX per FDA announce and the receptor the a our preparing meeting to novel fatty track data trial to continue patients liver beta of we roll half in
are programs stores glycogen disease we rare X-linked our disease adrenoleukodystrophy. Lastly, targeting advancing and
in We for your Each for to to statements initiate questions. GSD a Ia later support trial today. future weeks, now our VKXXXX studies This the IND year. this of in us for complete prepared call. open expect these Viking. concludes to opportunities for I’d on enabling today's line plan VKXXXX exciting coming the and for Operator? And and and X-ALD represent proof-of-concept thanks Thanks like we programs for for joining
